TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications

G. Novo, N. Caplice, R. Tantillo, F. Bonura, R. Simari, S. Novo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim. In patients with atherosclerosis there is an activation of the tissue factor mediated coagulation cascade. The aim of our study was to ascertain if there is a relationship between increased tissue factor pathway inhibitor (TFPI) antigen and activity plasma levels and atherosclerosis. Methods. Design: case-control study. Setting: Department of Internal Medicine and Cardiovascular Diseases, University of Palermo and Laboratory of Genetics and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Patients: 63 consecutive patients with asymptomatic atherosclerosis or with its acute or chronic complications, and 20 healthy volunteers. Measurements: TFPI antigen was detected by an immunoenzimatic assay (Imunobind total TFPI ELISA kit, American Diagnostica Inc., USA). TFPI activity was evaluated by an activity assay (Actichrome TFPI activity assay, American Diagnostica Inc., USA). Results. Patients with chronic (P=0.0001 for TFPI Ag, P=0.006 for TFPI Ac) and acute (P=0.04 for TFPI Ag, P=0.0 1 for TFPI Ac) vascular disease and with asymptomatic carotid plaque (P=0.0019 for TFPI Ag, P<0.05 for TFPI Ac) had significantly increased TFPI antigen and activity plasma levels vs healthy volunteers. Moreover, patients with chronic vascular disease had higher TFPI Ag levels vs patients with asymptomatic atherosclerosis (P=0.0013). Conclusion. The originality of our study was the finding of increased TFPI levels, not only in patients with acute complication of atherosclerosis, but also in those with chronic vascular disease and with asymptormatic carotid plaque.

Original languageEnglish (US)
Pages (from-to)366-371
Number of pages6
JournalInternational Angiology
Volume24
Issue number4
StatePublished - Dec 2005

Fingerprint

Atherosclerosis
Antigens
Vascular Diseases
lipoprotein-associated coagulation inhibitor
Healthy Volunteers
Chronic Disease
Thromboplastin
Internal Medicine
Case-Control Studies
Molecular Biology
Cardiovascular Diseases
Enzyme-Linked Immunosorbent Assay

Keywords

  • Atherosclerosis
  • Carotid diseases
  • Cerebrovascular accident
  • Myocardial infarction
  • Peripheral arterial diseases
  • Stroke
  • TFPI activity
  • TFPI antigen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Novo, G., Caplice, N., Tantillo, R., Bonura, F., Simari, R., & Novo, S. (2005). TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. International Angiology, 24(4), 366-371.

TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. / Novo, G.; Caplice, N.; Tantillo, R.; Bonura, F.; Simari, R.; Novo, S.

In: International Angiology, Vol. 24, No. 4, 12.2005, p. 366-371.

Research output: Contribution to journalArticle

Novo, G, Caplice, N, Tantillo, R, Bonura, F, Simari, R & Novo, S 2005, 'TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications', International Angiology, vol. 24, no. 4, pp. 366-371.
Novo, G. ; Caplice, N. ; Tantillo, R. ; Bonura, F. ; Simari, R. ; Novo, S. / TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. In: International Angiology. 2005 ; Vol. 24, No. 4. pp. 366-371.
@article{6bcc50870c274d1fb9e889c55b1d3ac5,
title = "TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications",
abstract = "Aim. In patients with atherosclerosis there is an activation of the tissue factor mediated coagulation cascade. The aim of our study was to ascertain if there is a relationship between increased tissue factor pathway inhibitor (TFPI) antigen and activity plasma levels and atherosclerosis. Methods. Design: case-control study. Setting: Department of Internal Medicine and Cardiovascular Diseases, University of Palermo and Laboratory of Genetics and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Patients: 63 consecutive patients with asymptomatic atherosclerosis or with its acute or chronic complications, and 20 healthy volunteers. Measurements: TFPI antigen was detected by an immunoenzimatic assay (Imunobind total TFPI ELISA kit, American Diagnostica Inc., USA). TFPI activity was evaluated by an activity assay (Actichrome TFPI activity assay, American Diagnostica Inc., USA). Results. Patients with chronic (P=0.0001 for TFPI Ag, P=0.006 for TFPI Ac) and acute (P=0.04 for TFPI Ag, P=0.0 1 for TFPI Ac) vascular disease and with asymptomatic carotid plaque (P=0.0019 for TFPI Ag, P<0.05 for TFPI Ac) had significantly increased TFPI antigen and activity plasma levels vs healthy volunteers. Moreover, patients with chronic vascular disease had higher TFPI Ag levels vs patients with asymptomatic atherosclerosis (P=0.0013). Conclusion. The originality of our study was the finding of increased TFPI levels, not only in patients with acute complication of atherosclerosis, but also in those with chronic vascular disease and with asymptormatic carotid plaque.",
keywords = "Atherosclerosis, Carotid diseases, Cerebrovascular accident, Myocardial infarction, Peripheral arterial diseases, Stroke, TFPI activity, TFPI antigen",
author = "G. Novo and N. Caplice and R. Tantillo and F. Bonura and R. Simari and S. Novo",
year = "2005",
month = "12",
language = "English (US)",
volume = "24",
pages = "366--371",
journal = "International Angiology",
issn = "0392-9590",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications

AU - Novo, G.

AU - Caplice, N.

AU - Tantillo, R.

AU - Bonura, F.

AU - Simari, R.

AU - Novo, S.

PY - 2005/12

Y1 - 2005/12

N2 - Aim. In patients with atherosclerosis there is an activation of the tissue factor mediated coagulation cascade. The aim of our study was to ascertain if there is a relationship between increased tissue factor pathway inhibitor (TFPI) antigen and activity plasma levels and atherosclerosis. Methods. Design: case-control study. Setting: Department of Internal Medicine and Cardiovascular Diseases, University of Palermo and Laboratory of Genetics and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Patients: 63 consecutive patients with asymptomatic atherosclerosis or with its acute or chronic complications, and 20 healthy volunteers. Measurements: TFPI antigen was detected by an immunoenzimatic assay (Imunobind total TFPI ELISA kit, American Diagnostica Inc., USA). TFPI activity was evaluated by an activity assay (Actichrome TFPI activity assay, American Diagnostica Inc., USA). Results. Patients with chronic (P=0.0001 for TFPI Ag, P=0.006 for TFPI Ac) and acute (P=0.04 for TFPI Ag, P=0.0 1 for TFPI Ac) vascular disease and with asymptomatic carotid plaque (P=0.0019 for TFPI Ag, P<0.05 for TFPI Ac) had significantly increased TFPI antigen and activity plasma levels vs healthy volunteers. Moreover, patients with chronic vascular disease had higher TFPI Ag levels vs patients with asymptomatic atherosclerosis (P=0.0013). Conclusion. The originality of our study was the finding of increased TFPI levels, not only in patients with acute complication of atherosclerosis, but also in those with chronic vascular disease and with asymptormatic carotid plaque.

AB - Aim. In patients with atherosclerosis there is an activation of the tissue factor mediated coagulation cascade. The aim of our study was to ascertain if there is a relationship between increased tissue factor pathway inhibitor (TFPI) antigen and activity plasma levels and atherosclerosis. Methods. Design: case-control study. Setting: Department of Internal Medicine and Cardiovascular Diseases, University of Palermo and Laboratory of Genetics and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Patients: 63 consecutive patients with asymptomatic atherosclerosis or with its acute or chronic complications, and 20 healthy volunteers. Measurements: TFPI antigen was detected by an immunoenzimatic assay (Imunobind total TFPI ELISA kit, American Diagnostica Inc., USA). TFPI activity was evaluated by an activity assay (Actichrome TFPI activity assay, American Diagnostica Inc., USA). Results. Patients with chronic (P=0.0001 for TFPI Ag, P=0.006 for TFPI Ac) and acute (P=0.04 for TFPI Ag, P=0.0 1 for TFPI Ac) vascular disease and with asymptomatic carotid plaque (P=0.0019 for TFPI Ag, P<0.05 for TFPI Ac) had significantly increased TFPI antigen and activity plasma levels vs healthy volunteers. Moreover, patients with chronic vascular disease had higher TFPI Ag levels vs patients with asymptomatic atherosclerosis (P=0.0013). Conclusion. The originality of our study was the finding of increased TFPI levels, not only in patients with acute complication of atherosclerosis, but also in those with chronic vascular disease and with asymptormatic carotid plaque.

KW - Atherosclerosis

KW - Carotid diseases

KW - Cerebrovascular accident

KW - Myocardial infarction

KW - Peripheral arterial diseases

KW - Stroke

KW - TFPI activity

KW - TFPI antigen

UR - http://www.scopus.com/inward/record.url?scp=30844456407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30844456407&partnerID=8YFLogxK

M3 - Article

C2 - 16355095

AN - SCOPUS:30844456407

VL - 24

SP - 366

EP - 371

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 4

ER -